DAC-1522 / DaCure Therapeutics - LARVOL DELTA

Discovery and characterization of DAC-1522, a novel Trop2-targeting degrader-antibody conjugate for precision oncology (AACR 2025) - "Despite the clinical success of Trop2-targeting ADCs like IMMU-132 (sacituzumab govitecan-hziy), their dependence on topoisomerase inhibitors as payloads has exposed significant limitations, particularly in addressing both intrinsic and acquired drug resistance. No obvious safety concerns were observed. These findings support further preclinical and clinical development of DAC-1522 as a highly promising therapeutic candidate for the Trop2-expressing cancers."

Oncology • Pancreatic Cancer • Solid Tumor • TACSTD2